AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by research analysts at Jefferies Financial Group in a research report issued on Wednesday, Digital Look reports. They currently have a £175 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target would suggest a potential upside of 45.69% from the company’s previous close.

Other research analysts also recently issued reports about the stock. Berenberg Bank restated a “buy” rating and issued a £175 price target on shares of AstraZeneca in a research report on Wednesday, October 7th. Citigroup boosted their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Royal Bank Of Canada reiterated an “outperform” rating and set a £145 price objective on shares of AstraZeneca in a research note on Tuesday, September 8th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 price objective on shares of AstraZeneca in a research note on Tuesday, September 29th. Six analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of £153.57.

AstraZeneca Stock Up 0.1%

AZN stock opened at £120.11 on Wednesday. The company has a debt-to-equity ratio of 64.10, a current ratio of 0.89 and a quick ratio of 0.59. AstraZeneca has a 1-year low of £114.04 and a 1-year high of £157.32. The firm has a fifty day moving average price of £120.45 and a two-hundred day moving average price of £131.94. The firm has a market cap of £186.29 billion, a price-to-earnings ratio of 17.98, a PEG ratio of 0.86 and a beta of 0.20.

Insider Buying and Selling

In related news, insider Michel Demare bought 2,500 shares of the company’s stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of £121.21 per share, with a total value of £303,025. 0.15% of the stock is currently owned by insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.